This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Bimatoprost ocular with preservative


Eye drops containing bimatoprost with preservative.

Drugs List

  • bimatoprost 100microgram/ml eye drops
  • bimatoprost 300microgram/ml eye drops
  • LUMIGAN 100microgram/1ml eye drops
  • Therapeutic Indications


    Treatment of elevated intraocular pressure in chronic open-angle glaucoma
    Treatment of elevated intraocular pressure in ocular hypertension

    As monotherapy or as adjunctive therapy to beta-blockers in the treatment of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults.



    Instil one drop into the affected eye(s) once daily in the evening.

    Do not exceed the once daily dose, as more frequent use may lessen the intraocular pressure lowering effect.


    Children under 18 years

    Precautions and Warnings

    Predisposition to hypotension
    Predisposition to iritis
    Predisposition to low heart rate
    Predisposition to uveitis
    Risk factors for cystoid macular oedema
    Wearing of contact lenses
    Chronic obstructive pulmonary disease
    History of viral ocular infection
    Moderate hepatic impairment
    Ocular inflammation
    Pseudophakia with torn posterior lens capsule
    Renal impairment
    Respiratory impairment

    Advise patient blurred vision may affect ability to drive/operate machinery
    Contains benzalkonium chloride
    Advise patient hair growth may occur on areas of skin repeatedly exposed
    In combined therapy, administer eye products at least five minutes apart
    To reduce systemic absorption compress lacrimal sac during administration
    Advise patient that some eye changes may be permanent
    Contains phosphate: Risk of calcification in existing notable cornea damage
    Advise patient to avoid touching the eye/other surfaces with container tip
    Before initiating treatment inform patient of possibility of eyelash growth
    Before initiating treatment inform patient of risk of eyelid skin darkening
    Before starting treatment inform patient of risk of increased iris pigment
    Remove contact lenses before use and re-insert 15 minutes after use

    Before treatment begins, advise patients there is a risk of prostaglandin analogue periorbitopathy (PAP). Some changes may be permanent and lead to an impaired field of vision. In cases where only one eye is treated there might be differences in appearance between eyes.

    Pregnancy and Lactation


    Use bimatoprost with caution during pregnancy.

    The manufacturer notes that bimatoprost eye drops should only be used in pregnancy if necessary. There is limited data for the use of bimatoprost in pregnant women and it is unknown if bimatoprost crosses the human placenta. Animal studies indicate a low risk.


    Bimatoprost is contraindicated during breastfeeding.

    The manufacturer notes that the decision must be taken to cease breastfeeding or to discontinue the medication. There is limited data for the use of bimatoprost eye drops during human breastfeeding. The molecular weight (around 416) and moderate plasma protein binding (around 88%) indicates that it will be excreted into breast milk, yet the very low blood concentration and short elimination half life indicates that notable exposure will not occur.

    Side Effects

    Abnormal liver function tests
    Allergic conjunctivitis
    Allergic dermatitis
    Blepharal pigmentation
    Blurred vision (transient)
    Conjunctival hyperaemia
    Conjunctival oedema
    Corneal erosion
    Cystoid macular oedema
    Dry eyes
    Dry skin
    Exacerbation of obstructive pulmonary disease
    Exacerbation of pre-existing asthma
    Eye pain
    Eyelash darkening
    Eyelash growth
    Eyelid changes
    Eyelid erythema
    Eyelid oedema
    Eyelid pruritus
    Eyelid retraction
    Eyelid sulcus
    Hair growth abnormal
    Hyperpigmentation of skin
    Hypersensitivity reactions
    Increased iris pigmentation
    Increased lacrimation
    Lid margin crusting
    Macular oedema
    Ocular allergy
    Ocular burning
    Ocular discharge
    Ocular discomfort
    Ocular irritation
    Ocular oedema
    Ocular pruritus
    Periorbital changes
    Periorbital erythema
    Periorbital skin pigmentation
    Punctate keratitis
    Reduced visual acuity
    Retinal haemorrhage
    Sensation of foreign body in eye
    Visual disturbances


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: June 2022

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Summary of Product Characteristics: Bimatoprost 0.1mg/ml eye drops, solution. Aspire Pharma Ltd. Revised May 2022.

    Summary of Product Characteristics: Bimatoprost 0.3mg/ml eye drops, solution. Aspire Pharma Ltd. Revised May 2022.

    Summary of Product Characteristics: Lumigan 0.1mg/ml eye drops, solution. AbbVie Ltd. Revised April 2022.

    NICE Evidence Services Available at: Last accessed: 17 June 2022

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.